Your browser doesn't support javascript.
loading
Long-term effects of pollen allergoid tyrosine-adsorbed subcutaneous immunotherapy on allergic rhinitis and asthma.
Vogelberg, Christian; Klimek, Ludger; Kruppert, Silvia; Becker, Sven.
Afiliación
  • Vogelberg C; Department of Pediatric Pneumology and Allergology, Faculty of Medicine and University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Dresden, Germany.
  • Klimek L; Center for Rhinology and Allergy, Wiesbaden, Germany.
  • Kruppert S; IQVIA, Frankfurt, Germany.
  • Becker S; Department of Otorhinolaryngology, Head and Neck Surgery, University of Tübingen, Tübingen, Germany.
Clin Exp Allergy ; 54(4): 253-264, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38146840
ABSTRACT

BACKGROUND:

Allergen immunotherapy (AIT) may have a long-term disease-modifying effect. The aim of this study was to demonstrate the long-term effects of pollen allergoid tyrosine-adsorbed subcutaneous AIT on allergic rhinitis (AR) and asthma (AA) in clinical practice.

METHODS:

This retrospective study, funded by an AIT manufacturer, analysed the impact of AIT on AR progression and onset of need for AA medication, using a German database covering ~35% of national prescriptions during 2008-2020. Anonymized prescription data of AR patients aged 5-65 years treated with grass or tree pollen AIT between 2009 and 2013 and followed for at least 2 years after AIT cessation were compared with matched control patients with seasonal AR.

RESULTS:

181,496 patients received AIT prescriptions. 5959 fulfilled the inclusion criteria. The median AIT treatment duration was 1092 days and the follow-up duration was 6.4 years. Less patients treated with AIT received prescriptions for symptomatic AR medication in the follow-up versus controls (AIT OR 0.37; 95% Confidence Interval (CI) 0.34, 0.40; p < .001, tyrosine-adsorbed AIT OR 0.27; 95% CI 0.20, 0.35 p < .001). Less asthmatic patients under AIT received prescriptions for AA medications versus controls (AIT OR 0.48; 95% CI 0.41, 0.55; p < .001, tyrosine-adsorbed AIT OR 0.48; 95% CI 0.29, 0.79; p = .004). AR and AA medication prescriptions for AIT patients were reduced in the follow-up versus baseline and controls (AIT AR 20.0%; 1.5 vs. 0.2 prescriptions; AA 29.1%; 2.0 vs. 0.6 prescriptions, p < .001; tyrosine-adsorbed AIT AR 24.2%, 1.4 vs. 0.2 prescriptions; AA 35.6%, 2.1 vs. 0.6 prescriptions, p < .001). The probability of AA medication onset in non-asthmatic patients during follow-up was reduced for AIT patients compared to controls (OR 0.77, 95% CI 0.66, 0.90; p = .001). All endpoints were significant for children/adolescents and adults in stratified analyses.

CONCLUSIONS:

We found evidence for long-term effects up to 9.5 years for tyrosine-adsorbed AIT.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Asma / Rinitis Alérgica Límite: Adolescent / Adult / Child / Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Asma / Rinitis Alérgica Límite: Adolescent / Adult / Child / Humans Idioma: En Año: 2024 Tipo del documento: Article